Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

Fig. 1

Changes in disease activity, serum biomarker, and CZP levels. A Changes in the DAS28(ESR) from baseline to 12 weeks after initiation of CZP therapy, mean ± SD, *p < 0.01 according to paired t test: DAS28(ESR) at each time points vs. baseline. B Classification of disease activity by the DAS28(ESR) and changes in disease activity at 12 weeks after CZP administration. Numbers represent percentages of all patients (%). C Left panel: changes in serum TNFα concentration up to 48 h after the CZP therapy, right panel: changes in serum IL-6 concentration up to 48 h after CZP initiation; data are shown as median (IQR). D Changes in serum CZP concentration up to 48 h after the CZP initiation; data are shown as mean ± SD

Back to article page